SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ADVENTRX Pharmaceuticals Inc (Anx)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: Keith Feral5/29/2007 9:48:07 AM
Read Replies (2) of 418
 
I was looking at the confidence levels from avastin, oxiplatin, and irinotecan clinical trials. All these trials are using drugs vs. basic standard of care - bolus or infusional Leucovorin/5FU. It is amazing to see the increase in toxicity as new chemo agents are introduced in all of the trial. 87% are receiving grade 3 or 4 toxicity.

gene.com

products.sanofi-aventis.us

patient.cancerconsultants.com

Herein lies the most amazing observation about Adventrx, which seeks to replace leucovorin with a direct form of folate - Cofactor. It achieves nearly the same response rate and survival rates as oxaliplatin or irinotecan, while it eliminates almost all grade 3 and grade 4 toxicity.

ILF (leucovorin/5FU and irinotecan)

Time to tumor progression - 6.4 months
34.8% response rate
15.6 months median survival

FOLFOX

Time to tumor progression - 8.8 months
38% response rate
18.6 months median survival

Oxaliplatin & Irinotecan

Time to tumor progression - 6.7 months
28% response rate
16.5 months median survival

Avastin plus IFL

Time to tumor progression - 10.6 month
44.8% response rate
20.3 months median survival

Cofactor – phase 2 study US

Time to tumor progression – 5.3 months
35% response rate
15.1 months survival rate
No Side Effects – hematological or gastrointestinal

Cofactor – Various Second Line Treatment – phase 2 US

23.0 months median survival rate
21.5 months Folfiri (n=109)
20.6 months Folfox6 (n=111)

Leucovorin

Time to tumor progression – 4 months
21% response rate
11.7 months median survival
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News